{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zou H"],"funding":["Michael J Fox Foundation for Parkinson&apos;s Research","NIA NIH HHS"],"pagination":["107118"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12418693"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["128"],"pubmed_abstract":["<h4>Introduction</h4>Tracking of emergent symptoms (ES) in de novo Parkinson Disease (PD) patients using Parts Ib and II of the MDS-UPDRS rating scale has been proposed as an outcome measure for PD clinical trials, based on observations in the Safety, Tolerability and Efficacy Assessment of Isradipine for PD (STEADY-PD3) clinical trial.<h4>Methods</h4>Individual item-level data was extracted from the SURE-PD3 study (coded as \"PD-1018\" in the C-path pooled dataset). We sought to confirm the observations made in the STEADY-PD3 dataset by analyzing data from a different Phase 3 clinical trial, the Phase 3 Study of Urate Elevation in Parkinson Disease (SURE-PD3), in which MDS-UPDRS was assessed more frequently than the 12-month intervals in STEADY-PD3, using similar methodology.<h4>Results</h4"],"journal":["Parkinsonism & related disorders"],"pubmed_title":["Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials."],"pmcid":["PMC12418693"],"funding_grant_id":["R01 AG064803","P30 AG072958"],"pubmed_authors":["Zou H","Stebbins GT","Cedarbaum JM","Simuni T","Luo S"],"additional_accession":[]},"is_claimable":false,"name":"Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials.","description":"<h4>Introduction</h4>Tracking of emergent symptoms (ES) in de novo Parkinson Disease (PD) patients using Parts Ib and II of the MDS-UPDRS rating scale has been proposed as an outcome measure for PD clinical trials, based on observations in the Safety, Tolerability and Efficacy Assessment of Isradipine for PD (STEADY-PD3) clinical trial.<h4>Methods</h4>Individual item-level data was extracted from the SURE-PD3 study (coded as \"PD-1018\" in the C-path pooled dataset). We sought to confirm the observations made in the STEADY-PD3 dataset by analyzing data from a different Phase 3 clinical trial, the Phase 3 Study of Urate Elevation in Parkinson Disease (SURE-PD3), in which MDS-UPDRS was assessed more frequently than the 12-month intervals in STEADY-PD3, using similar methodology.<h4>Results</h4","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-02T17:38:55.68Z","creation":"2026-04-18T03:11:19.31Z"},"accession":"S-EPMC12418693","cross_references":{"pubmed":["39353265"],"doi":["10.1016/j.parkreldis.2024.107118"]}}